1 Department of Pharmacy, Poltekkes Kemenkes Medan, Indonesia.
2 Hemodialysis Unit Haji Adam Malik Hospital Medan, Indonesia.
World Journal of Advanced Research and Reviews, 2021, 10(01), 289-295
Article DOI: 10.30574/wjarr.2021.10.1.0170
DOI url: https://doi.org/10.30574/wjarr.2021.10.1.0170
Received on 16 March 2021; revised on 20 April 2021; accepted on 22 April 2021
Objective: To elicit quality of life of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin from clinical and humanistic outcome, to analysis characteristic factors to Hb, fatique and the quality of life (QOL) of CKD patients with routine hemodialysis, and to explore the change in QOL over one month for patients managed in the hospitals.
Methods: A prospective study was conducted among adult CKD patients in Haji Adam Malik Hospital Medan. QOL was measured using kidney disease quality of life – short form (KDQOL–SFTM) questionnaire and FACIT fatigue scale questionnaire. CKD patients. Patients were asked to complete the KDQOL–SFTM questionnaire and FACIT fatigue scale questionnaire two times in one month range.
Results: Average rate of haemoglobin was increased after one month anemia treatment using erythropoietin 8.68: 8.82. Average rate of FACIT was increased after one month anemia treatment using erythropoietin 43.98: 44.81. Average rate of KDQOL was increased after one month anemia treatment using erythropoietin 76.83: 77.94.
Conclusion: Erythropoietin can improve QOL of CKD patients with routine hemodialysis.
CKD; Hemodialysis; QOL; Erythropoietin
Preview Article PDF
Sihombing JP, Nasution AT and Sitanggang H. Quality of life of CKD patients with routine hemodialysis in Haji Adam Malik Hospital Medan. World Journal of Advanced Research and Reviews, 2021, 10(01), 289-295. Article DOI: https://doi.org/10.30574/wjarr.2021.10.1.0170
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0